Merrimack rallies after providing Q3 results, operational update

Merrimack Pharmaceuticals (MACK +17.6%) jumps after providing an update on its development program along with Q3 results.

NAPOLI-1 (MM-398 in advanced pancreatic cancer) top-line data now expected in Q2 2014 versus Q4 2013/Q1 2014. MACK says a "blinded assessment of OS events across the entire trial ... are occurring later than forecasted."

Confirmed: MM-121 Phase 2 in wild-type EGFR non-small cell lung cancer did not meet primary endpoint.

Upcoming in Q4: Top-line data for MM-121 in second line hormone receptor positive breast cancer, neoadjuvant HER2 negative breast cancer; presentation of MM-302 Phase 1 in December.

Financials: Q3 net loss of $0.39 versus consensus of a $0.31 loss.

Cash and equivalents along with interest income and funding from the Sanofi collaboration expected "to be sufficient to fund operations into 2015." (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs